Description_x000D_ Application_x000D_ Cyproheptadine hydrochloride sesquihydrate has been used in:_x000D_ • testing anti-inflammatory activity in serotonin receptor (5-HT) induced inflammation_x000D_ • the inhibition of 5-HT in in vivo and in vitro bioassays in crabs_x000D_ • the inhibition of 5-HT in embryo physiological experiments_x000D_ inhibition of calcitonin gene related peptide (CGRP)_x000D_ Packaging_x000D_ 1 g in poly bottle_x000D_ 100 mg in poly bottle_x000D_ Biochem/physiol Actions_x000D_ Cyproheptadine hydrochloride sesquihydrate is a serotonin receptor (5-HT2/5-HT1C) antagonist, H1 histamine receptor antagonist and an antipruritic. The inhibition of 5-HT by cyproheptadine improves cognitive function in schizophrenia disorder. Cyproheptadine is effective for treating functional gastrointestinal disorders (FGIDs). Food and Drug Administration (FDA) approved cyproheptadine, has antidepressant and antiplatelet functionality. It may be effective in treating thromboembolic disorders. Cyproheptadine inhibits lysine methyltransferase 7/9 (Set7/9) leading to a decrease in estrogen receptor (ERα) expression and growth arrest in breast cancer cells._x000D_ Features and Benefits_x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Legal Information_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC